Mouse Recombinant OPCML protein, His Tag (V2LY-0526-LY8725)

Khamko, R., Wasenang, W., Daduang, J., Settasatian, C., & Limpaiboon, T. (2022). Combined OPCML and AXL expression as a prognostic marker and OPCML enhances AXL inhibitor in cholangiocarcinoma. in vivo, 36(3), 1168-1177.

Zhang, Y., Sun, X., Zhang, Y., Kang, Z., Cai, L., Ding, J., ... & Hu, G. (2022). GPBAR1 preserves neurite and synapse of dopaminergic neurons via RAD21-OPCML signaling: Role in preventing Parkinson's disease in mouse model and human patients. Pharmacological Research, 184, 106459.

Shao, Y., Kong, J., Xu, H., Wu, X., Cao, Y., Li, W., ... & Wu, J. (2021). OPCML methylation and the risk of ovarian cancer: a meta and bioinformatics analysis. Frontiers in Cell and Developmental Biology, 9, 570898.

Antony, J., Zanini, E., Birtley, J. R., Gabra, H., & Recchi, C. (2021). Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers. Cancer Gene Therapy, 28(1), 18-26.

Lian, B., Li, H., Liu, Y., Chai, D., Gao, Y., Zhang, Y., ... & Li, J. (2021). Expression and promoter methylation status of OPCML and its functions in the inhibition of cell proliferation, migration, and invasion in breast cancer. Breast Cancer, 28, 448-458.

Fang, X., Dong, Y., Yang, R., & Wei, L. (2020). LINC00619 restricts gastric cancer progression by preventing microRNA-224-5p-mediated inhibition of OPCML. Archives of biochemistry and biophysics, 689, 108390.

Simovic, I., Castaño-Rodríguez, N., & Kaakoush, N. O. (2019). OPCML: a promising biomarker and therapeutic avenue. Trends in Cancer, 5(8), 463-466.

Zhang, Z., Ye, M., Li, Q., You, Y., Yu, H., Ma, Y., ... & Zhang, D. (2019). The schizophrenia susceptibility gene OPCML regulates spine maturation and cognitive behaviors through Eph-Cofilin signaling. Cell Reports, 29(1), 49-61.

Wasenang, W., Chaiyarit, P., Proungvitaya, S., & Limpaiboon, T. (2019). Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases. Clinical Epigenetics, 11, 1-10.

Birtley, J. R., Alomary, M., Zanini, E., Antony, J., Maben, Z., Weaver, G. C., ... & Gabra, H. (2019). Inactivating mutations and X-ray crystal structure of the tumor suppressor OPCML reveal cancer-associated functions. Nature communications, 10(1), 3134.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols